Title: Association Between GLP-1 Receptor Agonists as a Class and Colorectal Cancer Risk:
A Meta-Analysis of Retrospective Cohort Studies
Version: 0 Date: 19 May 2025
Reviewer's report:
Thank you very much for giving me the opportunity to review the current manuscript. Authors
conducted a meta-analysis to evaluated the effect of Glucagon-like peptide-1 receptor agonists
on CRC. They have added seven retrospective cohort studies by searching on data bases of
PubMed, Embase, and Cochrane Library. The study suggests a significantly increased risk of
colorectal cancer associated with GLP-1 RA use in patients. The topic is of interest and in line
with the scope of the journal.
I have some comments for authors:
1. Please design a graphical abstract for your manuscript.
2. Please edit your submission and try to use “patients with T2DM” instead of “T2DM patients”.
3. In the first line of your introduction part, you state the usage of GLP-1 Ras in patients “with
and without obesity”. Can you explain the reason for this phrase?
4. You should say more information regarding T2DM and its epidemiological status worldwide.
You can use these articles: https://doi.org/10.2174/0115733998284844240102110559 and
https://doi.org/10.1016/j.dsx.2024.103110
5. As you investigated the relationship between CRC and GLP-1 Ras, it is necessary to discuss
about the epidemiological status of CRC as a GI cancer. You may use these articles for your
text: 10.4103/sjg.sjg_163_23 and 10.1038/s41598-023-44487-8.
6. Add S as “Study type” in your PICO criteria.
7. Please state the cause of 663 data exclusion in the last section of your PRISMA chart (e.g,,
27 articles for different languages and …)
8. I see that in one of your articles, patients with PCOS were assessed for analysis. I think that
the underlying disease could effect on the final outcomes in your manuscript. What did you do
for this effect?
9. I see that some of your references are out of date. Please recheck them and try to update your
references to be at least for 2017 and above.
Title: Association Between GLP-1 Receptor Agonists as a Class and Colorectal Cancer Risk:
A Meta-Analysis of Retrospective Cohort Studies
Version: 0 Date: 19 May 2025
Reviewer's report:
Thank you very much for giving me the opportunity to review the current manuscript. Authors
conducted a meta-analysis to evaluated the effect of Glucagon-like peptide-1 receptor agonists
on CRC. They have added seven retrospective cohort studies by searching on data bases of
PubMed, Embase, and Cochrane Library. The study suggests a significantly increased risk of
colorectal cancer associated with GLP-1 RA use in patients. The topic is of interest and in line
with the scope of the journal.
I have some comments for authors:
1. Please design a graphical abstract for your manuscript.
2. Please edit your submission and try to use “patients with T2DM” instead of “T2DM patients”.
3. In the first line of your introduction part, you state the usage of GLP-1 Ras in patients “with
and without obesity”. Can you explain the reason for this phrase?
4. You should say more information regarding T2DM and its epidemiological status worldwide.
You can use these articles: https://doi.org/10.2174/0115733998284844240102110559 and
https://doi.org/10.1016/j.dsx.2024.103110
5. As you investigated the relationship between CRC and GLP-1 Ras, it is necessary to discuss
about the epidemiological status of CRC as a GI cancer. You may use these articles for your
text: 10.4103/sjg.sjg_163_23 and 10.1038/s41598-023-44487-8.
6. Add S as “Study type” in your PICO criteria.
7. Please state the cause of 663 data exclusion in the last section of your PRISMA chart (e.g,,
27 articles for different languages and …)
8. I see that in one of your articles, patients with PCOS were assessed for analysis. I think that
the underlying disease could effect on the final outcomes in your manuscript. What did you do
for this effect?
9. I see that some of your references are out of date. Please recheck them and try to update your
references to be at least for 2017 and above.
Please review this paper.
user
Title: Association Between GLP-1 Receptor Agonists as a Class and Colorectal Cancer Risk:
A Meta-Analysis of Retrospective Cohort Studies
Version: 0 Date: 19 May 2025
Reviewer's report:
Thank you very much for giving me the opportunity to review the current manuscript. Authors
conducted a meta-analysis to evaluated the effect of Glucagon-like peptide-1 receptor agonists
on CRC. They have added seven retrospective cohort studies by searching on data bases of
PubMed, Embase, and Cochrane Library. The study suggests a significantly increased risk of
colorectal cancer associated with GLP-1 RA use in patients. The topic is of interest and in line
with the scope of the journal.
I have some comments for authors:
1. Please design a graphical abstract for your manuscript.
2. Please edit your submission and try to use “patients with T2DM” instead of “T2DM patients”.
3. In the first line of your introduction part, you state the usage of GLP-1 Ras in patients “with
and without obesity”. Can you explain the reason for this phrase?
4. You should say more information regarding T2DM and its epidemiological status worldwide.
You can use these articles: https://doi.org/10.2174/0115733998284844240102110559 and
https://doi.org/10.1016/j.dsx.2024.103110
5. As you investigated the relationship between CRC and GLP-1 Ras, it is necessary to discuss
about the epidemiological status of CRC as a GI cancer. You may use these articles for your
text: 10.4103/sjg.sjg_163_23 and 10.1038/s41598-023-44487-8.
6. Add S as “Study type” in your PICO criteria.
7. Please state the cause of 663 data exclusion in the last section of your PRISMA chart (e.g,,
27 articles for different languages and …)
8. I see that in one of your articles, patients with PCOS were assessed for analysis. I think that
the underlying disease could effect on the final outcomes in your manuscript. What did you do
for this effect?
9. I see that some of your references are out of date. Please recheck them and try to update your
references to be at least for 2017 and above.
assistant